2018 American Transplant Congress
Closing Pandora's Box: An Evidence Based Approach to Opioid-Tolerant Patients Following Transplantation. The Case for IV Methadone
Department of Surgery, Beaumont Health, Royal Oak, MI.
The purpose of this study is to explore the use of parenteral methadone in opioid-tolerant patients who are status-post transplantation. As an alternative to traditional…2018 American Transplant Congress
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: Everolimus (EVR)-facilitated calcineurin inhibitor (CNI) reduction regimens help prevent long-term CNI nephrotoxicity in kidney transplant recipients (KTxRs). TRANSFORM (NCT01950819) is the largest study in…2018 American Transplant Congress
Qualitative Analysis of Facebook Posts Created via the Donor Application
The Donor App is a smartphone app that helps transplant candidates create a Facebook (FB) post telling their story about organ failure and their need…2018 American Transplant Congress
Pancreas Retransplantation: Outcomes of This Technical and Immunological Challenge over 38 Patients
IntroductionPancreas transplantation is now a mastered technique for patients suffering from severe diabetes. However, a significant number of grafts are lost for technical and immunological…2018 American Transplant Congress
BETA-2 Score is an Excellent Tool for Monitoring of Islet Allograft Function and Early Detection of Transplant Dysfunction
1Surgery, University of Chicago, Chicago; 2Nephrology, Medical University of Gdańsk, Gdańsk, Poland.
After validation of BETA-2 scores in our cohort of patients in relation to standard stimulation tests, we decided to assess the practical utility of BETA-2…2018 American Transplant Congress
Hospitality Houses and Transplant Patients: Assessing the Impact of a Hospitality House Dedicated to Transplant Patients and Their Families
Hospitality houses exclusively for transplant patients and their families are a relatively new concept and their connection to medical outcomes is untested. One hospitality house…2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients
University of Iowa Hospitals and Clinics, Iowa City, IA.
Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 14
- Next Page »